Targets › SLC18A3
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Apr 2027.
Electrogenic antiporter that exchanges one cholinergic neurotransmitter, acetylcholine or choline, with two intravesicular protons across the membrane of synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to store neurotransmitters inside the vesicles prior to their release via exocytosis (By similarity). (UniProt, Q16572)
Open in Phaseline: the race on SLC18A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanderbilt University Medical Center | [18F]-FEOBV Vesicular acetylcholine transporter (VAChT) imaging agent | SLC18A3 | Phase 2 | Down Syndrome | Apr 2027 |
Down Syndrome (1)
small molecule (1)
Vanderbilt University Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.